Literature DB >> 28100606

Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes.

Tamara Spaic1, Marsha Driscoll1, Dan Raghinaru2, Bruce A Buckingham3, Darrell M Wilson3, Paula Clinton3, H Peter Chase4, David M Maahs3,4, Gregory P Forlenza4, Emily Jost4, Irene Hramiak1, Terri Paul1, B Wayne Bequette5, Faye Cameron5, Roy W Beck2, Craig Kollman2, John W Lum6, Trang T Ly3.   

Abstract

OBJECTIVE: The objective of this study was to determine the safety, feasibility, and efficacy of a predictive hyperglycemia and hypoglycemia minimization (PHHM) system compared with predictive low-glucose insulin suspension (PLGS) alone in overnight glucose control. RESEARCH DESIGN AND METHODS: A 42-night trial was conducted in 30 individuals with type 1 diabetes in the age range 15-45 years. Participants were randomly assigned each night to either PHHM or PLGS and were blinded to the assignment. The system suspended the insulin pump on both the PHHM and PLGS nights for predicted hypoglycemia but delivered correction boluses for predicted hyperglycemia on PHHM nights only. The primary outcome was the percentage of time spent in a sensor glucose range of 70-180 mg/dL during the overnight period.
RESULTS: The addition of automated insulin delivery with PHHM increased the time spent in the target range (70-180 mg/dL) from 71 ± 10% during PLGS nights to 78 ± 10% during PHHM nights (P < 0.001). The average morning blood glucose concentration improved from 163 ± 23 mg/dL after PLGS nights to 142 ± 18 mg/dL after PHHM nights (P < 0.001). Various sensor-measured hypoglycemic outcomes were similar on PLGS and PHHM nights. All participants completed 42 nights with no episodes of severe hypoglycemia, diabetic ketoacidosis, or other study- or device-related adverse events.
CONCLUSIONS: The addition of a predictive hyperglycemia minimization component to our existing PLGS system was shown to be safe, feasible, and effective in overnight glucose control.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28100606      PMCID: PMC5319476          DOI: 10.2337/dc16-1794

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  34 in total

1.  Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.

Authors:  Steven J Russell; Mallory A Hillard; Courtney Balliro; Kendra L Magyar; Rajendranath Selagamsetty; Manasi Sinha; Kerry Grennan; Debbie Mondesir; Laya Ekhlaspour; Hui Zheng; Edward R Damiano; Firas H El-Khatib
Journal:  Lancet Diabetes Endocrinol       Date:  2016-02-03       Impact factor: 32.069

2.  Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp.

Authors:  Trang T Ly; Anirban Roy; Benyamin Grosman; John Shin; Alex Campbell; Salman Monirabbasi; Bradley Liang; Rie von Eyben; Satya Shanmugham; Paula Clinton; Bruce A Buckingham
Journal:  Diabetes Care       Date:  2015-06-06       Impact factor: 19.112

3.  2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.

Authors:  Jort Kropff; Simone Del Favero; Jerome Place; Chiara Toffanin; Roberto Visentin; Marco Monaro; Mirko Messori; Federico Di Palma; Giordano Lanzola; Anne Farret; Federico Boscari; Silvia Galasso; Paolo Magni; Angelo Avogaro; Patrick Keith-Hynes; Boris P Kovatchev; Daniela Bruttomesso; Claudio Cobelli; J Hans DeVries; Eric Renard; Lalo Magni
Journal:  Lancet Diabetes Endocrinol       Date:  2015-09-30       Impact factor: 32.069

4.  Multinight "bedside" closed-loop control for patients with type 1 diabetes.

Authors:  Sue A Brown; Boris P Kovatchev; Marc D Breton; Stacey M Anderson; Patrick Keith-Hynes; Stephen D Patek; Boyi Jiang; Najib Ben Brahim; Paul Vereshchetin; Daniela Bruttomesso; Angelo Avogaro; Simone Del Favero; Federico Boscari; Silvia Galasso; Roberto Visentin; Marco Monaro; Claudio Cobelli
Journal:  Diabetes Technol Ther       Date:  2015-01-16       Impact factor: 6.118

5.  The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group.

Authors: 
Journal:  Diabetes       Date:  1986-05       Impact factor: 9.461

6.  Inpatient studies of a Kalman-filter-based predictive pump shutoff algorithm.

Authors:  Fraser Cameron; Darrell M Wilson; Bruce A Buckingham; Hasmik Arzumanyan; Paula Clinton; H Peter Chase; John Lum; David M Maahs; Peter M Calhoun; B Wayne Bequette
Journal:  J Diabetes Sci Technol       Date:  2012-09-01

7.  Automated Overnight Closed-Loop Control Using a Proportional-Integral-Derivative Algorithm with Insulin Feedback in Children and Adolescents with Type 1 Diabetes at Diabetes Camp.

Authors:  Trang T Ly; D Barry Keenan; Anirban Roy; Jino Han; Benyamin Grosman; Martin Cantwell; Natalie Kurtz; Rie von Eyben; Paula Clinton; Darrell M Wilson; Bruce A Buckingham
Journal:  Diabetes Technol Ther       Date:  2016-05-16       Impact factor: 6.118

8.  Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis.

Authors:  Bruce A Buckingham; Dan Raghinaru; Fraser Cameron; B Wayne Bequette; H Peter Chase; David M Maahs; Robert Slover; R Paul Wadwa; Darrell M Wilson; Trang Ly; Tandy Aye; Irene Hramiak; Cheril Clarson; Robert Stein; Patricia H Gallego; John Lum; Judy Sibayan; Craig Kollman; Roy W Beck
Journal:  Diabetes Care       Date:  2015-06-06       Impact factor: 19.112

9.  Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.

Authors:  Hood Thabit; Alexandra Lubina-Solomon; Marietta Stadler; Lalantha Leelarathna; Emma Walkinshaw; Andrew Pernet; Janet M Allen; Ahmed Iqbal; Pratik Choudhary; Kavita Kumareswaran; Marianna Nodale; Chloe Nisbet; Malgorzata E Wilinska; Katharine D Barnard; David B Dunger; Simon R Heller; Stephanie A Amiel; Mark L Evans; Roman Hovorka
Journal:  Lancet Diabetes Endocrinol       Date:  2014-06-16       Impact factor: 32.069

10.  Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp.

Authors:  Trang T Ly; Marc D Breton; Patrick Keith-Hynes; Daniel De Salvo; Paula Clinton; Kari Benassi; Benton Mize; Daniel Chernavvsky; Jéróme Place; Darrell M Wilson; Boris P Kovatchev; Bruce A Buckingham
Journal:  Diabetes Care       Date:  2014-05-30       Impact factor: 19.112

View more
  6 in total

1.  Insulin Infusion Sets and Continuous Glucose Monitoring Sensors: Where the Artificial Pancreas Meets the Patient.

Authors:  Gregory P Forlenza
Journal:  Diabetes Technol Ther       Date:  2017-04       Impact factor: 6.118

2.  Role of continuous glucose monitoring in the management of glycogen storage disorders.

Authors:  Mrudu Herbert; Surekha Pendyal; Mugdha Rairikar; Carine Halaby; Robert W Benjamin; Priya S Kishnani
Journal:  J Inherit Metab Dis       Date:  2018-05-25       Impact factor: 4.982

3.  Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescents.

Authors:  Gregory P Forlenza; Dan Raghinaru; Faye Cameron; B Wayne Bequette; H Peter Chase; R Paul Wadwa; David M Maahs; Emily Jost; Trang T Ly; Darrell M Wilson; Lisa Norlander; Laya Ekhlaspour; Hyojin Min; Paula Clinton; Nelly Njeru; John W Lum; Craig Kollman; Roy W Beck; Bruce A Buckingham
Journal:  Pediatr Diabetes       Date:  2017-11-20       Impact factor: 4.866

Review 4.  Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy.

Authors:  Julia Fuchs; Roman Hovorka
Journal:  Expert Rev Med Devices       Date:  2020-07-03       Impact factor: 3.166

Review 5.  Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes.

Authors:  Martin Tauschmann; Roman Hovorka
Journal:  Expert Opin Drug Deliv       Date:  2017-08-18       Impact factor: 6.648

Review 6.  Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.

Authors:  Eleni Bekiari; Konstantinos Kitsios; Hood Thabit; Martin Tauschmann; Eleni Athanasiadou; Thomas Karagiannis; Anna-Bettina Haidich; Roman Hovorka; Apostolos Tsapas
Journal:  BMJ       Date:  2018-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.